Drug Trial Radar · NCT06855121
The Norwegian Immunotherapy in Multiple Myeloma Study
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jan 15, 2025
Primary completion
Jan 2029
Study completion Dec 1, 2037
Sponsor
- Lead sponsor
- St. Olavs HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Norwegian University of Science and Technology; Haukeland University Hospital; Helse Stavanger HF; Oslo University Hospital; University Hospital, Akershus; Sykehuset i Vestfold Hospital Trust; University Hospital of North Norway; Ålesund Hospital, Norway; Helse Nord-Trøndelag HF; Sorlandet Hospital HF; Førde Hospital Trust; Molde Hospital; Bodø Hospital, Norway; Helse Fonna; Volda Hospital; Diakonhjemmet Hospital; Telemark Hospital Trust; Kristiansund Hospital; Vestre Viken Hospital Trust; Lovisenberg Diakonale Hospital; Sykehuset Innlandet HF
- First posted
- Mar 3, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
Conditions
- Myeloma Multiple
- Plasma Cell Leukemia
- AL Amyloidosis
Interventions
TeclistamabDrug
Real-world use and dosing
ElranatamabDrug
Real-world use and dosing
Ciltacabtagene AutoleucelBiological
Real-world use.
TalquetamabDrug
Real-world use and dosing
Idecabtagene vicleucelBiological
Real-world use and dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the real-world overall response rates (ORR)Time frame: From date of treatment start and until date of first documented progression or start of next line of therapy, whichever came first, assessed up to ten years.
- Determine real-world progression-free survival (PFS)Time frame: From date of treatment start and until date of first documented progression or death, whichever came first, , assessed up to ten years.
- Determine real-world time-to-next treatment (TTNT)Time frame: From date of treatment start and until date of start of next treatment, assessed up to ten years.
- Determine real-world overall survival (OS)Time frame: From date of treatment start and until death, assessed up to ten years.
- Describe the frequency and grading of adverse events of special interest (AESI), defined as described below.Time frame: From date of treatment start until the date of start of next line of treatment or death, whichever came first, assessed up to 10 years
- Frequency and grading of all other adverse events occurring during treatment according to CTCAE 5.0 (only grade 3 or higher will be reported).Time frame: From start of treatment and until start of next treatment or death, assessed up to ten years.
- Describe the microbiological pattern (positive cultures/PCR) of infections during treatment.Time frame: From start of treatment and start of next treatment line or death, assessed up to ten years.
- Describe the antibiotic resistance pattern of positive cultures.Time frame: From start of treatment and start of next treatment line or death, assessed up to ten years.
- Describe the prevalence of common airway viruses during treatment and at end-of-treatment.Time frame: From date of start of treatment and until end of treatment, assessed up to ten years.
- Determine the real-world use of antimicrobial prophylaxis (antibiotics, antivirals, vaccines, immunoglobulines) before and during therapy.Time frame: From enrollment and until end of treatment, assessed up to ten years.
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Ålesund hospital, Department of hematology
Ålesund, Norway · Not yet recruiting
Sørlandet Hospital - Arendal
Arendal, Norway · Not yet recruiting
Bærum Hospital
Bærum, Norway · Not yet recruiting
Haukeland University Hospital
Bergen, Norway · Not yet recruiting
Bodø Hospital
Bodø, Norway · Not yet recruiting
Drammen hospital
Drammen, Norway · Not yet recruiting
Førde hospital
Førde, Norway · Not yet recruiting
Innlandet hospital trust
Gjøvik, Norway · Not yet recruiting
Haugesund hospital
Haugesund, Norway · Not yet recruiting
Sørlandet hospital
Kristiansand, Norway · Not yet recruiting
Nordmøre and Romsdal Hospital - Kristiansund
Kristiansund, Norway · Not yet recruiting
Levanger hospital
Levanger, Norway · Not yet recruiting
Nordmøre and Romsdal Hospital - Molde
Molde, Norway · Not yet recruiting
Akershus University Hospital (AHUS)
Nordbyhagen, Norway · Not yet recruiting
Diakonhjemmet hospital
Oslo, Norway · Not yet recruiting
Lovisenberg Diaconal Hospital
Oslo, Norway · Not yet recruiting
Oslo Myeloma Center, Oslo University Hospital
Oslo, Norway · Not yet recruiting
Telemark Hospital Trust
Skien, Norway · Not yet recruiting
Stavanger University hospital
Stavanger, Norway · Not yet recruiting
Vestfold Hospital Trust
Tønsberg, Norway · Not yet recruiting
University hospital of North Norway
Tromsø, Norway · Not yet recruiting
St. Olavs hospital HF
Trondheim, Norway · Recruiting
Volda hospital
Volda, Norway · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.